- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Suven Life Sciences reported Q2 consolidated net loss of ₹77.31 Cr and H1 loss of ₹128.83 Cr. The company raised ₹123.10 Cr by allotting 9.19M shares from warrant conversions, with ₹252.49 Cr balance from preferential issue. Multiple CNS drug candidates are in various clinical phases, plus 17 new patents.